Forbes Medi-Tech Increases Revenue Guidance Range 16% to $8.75 to $9.25 Million

"Our nutritional business has grown substantially in thelast two years with a strong presence in the European marketplaceand growing awareness in the U.S.," said Charles Butt, Presidentand CEO of Forbes Medi-Tech. "Factors included in the liftin revenue guidance are an increase in account activityand the sale of excess inventory partially offset by theimpact of the strengthening Canadian dollar against theU.S. dollar and the Euro. The sale of excess inventory hasaligned our remaining inventory with forecasted demand."

About Forbes Medi-Tech Inc.

Forbes Medi-Tech Inc. is a life sciences company dedicatedto the research, development and commercialization of innovativeproducts for the prevention and treatment of life-threateningdisease. Our strategy and vision is to develop and marketa portfolio of products for the benefit of all consumers,from the healthy person desiring consumer lifestyle productsthat can help reduce the risk of future disease, to medicalpatients needing therapeutic prescription products for thetreatment of an established ailment. Additional informationon Forbes Medi-Tech can be found at .

This News Release contains forward-looking statements andinformation regarding the Company's revenue guidance, forecastedsales, and Forbes' strategy and vision, which statementscan be identified by the use of forward-looking terminologysuch as "revenue guidance", "forecasted", "strategy" and"vision" or comparable terminology referring to future eventsor results. The Company's actual results could differ materiallyfrom those anticipated in these forward-looking statementsand information as a result of numerous factors, includingthe Company's need for additional funding in the near term,the availability and sufficiency of which is not assured;uncertainty whether the Company will be able to achieveits revenue guidance; the need for performance by buyersof the Company's products and the risk that they may notpurchase forecasted amounts; product liability and insurancerisks; the effect of competition; reliance by the Companyon its suppliers, manufacturers and customers for performance;uncertainty whether the Company will realize its strategiesand vision; intellectual property risks; manufacturing risksand the need to manufacture to regulatory standards; changesin business strategy or development plans; as well as adescription of other risks and uncertainties affecting theCompany and its business, as contained in news releasesand filings with Securities Regulatory Authorities in Canadaand the U.S., any of which could cause actual results tovary materially from current results or the Company's anticipatedfuture results. Forward-looking statements and informationare based on the beliefs, opinions and expectations of theCompany's management at the time they are made, and theCompany does not assume any obligation to update any statementshould those beliefs, opinions or expectations, or othercircumstances change.

NASDAQ and the Toronto Stock Exchange have not reviewedand do not accept responsibility for the adequacy or accuracyof the content of this News Release.